Status:
COMPLETED
Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
Lead Sponsor:
Dendreon
Conditions:
Metastatic Androgen Independent Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)
Eligibility Criteria
Inclusion
- Objective disease progression
- Subjects must have been enrolled in the APC-Placebo arm of D9902B (NCT00065442)
Exclusion
- Infection requiring IV antibiotics
- Treatment with anticancer interventions within 14 days prior to enrollment
- Any medical condition which could compromise the study's objectives (discretion from sponsor)
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT00849290
Start Date
April 1 2004
End Date
April 1 2009
Last Update
November 29 2023
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA
Los Angeles, California, United States
2
USC Keck School of Medicine
Los Angeles, California, United States
3
Sutter Cancer Center
Sacramento, California, United States
4
Kaiser Permanente Medical Group
San Diego, California, United States